Evidence map›Paper›PMID 40940979›Full record

ArticleCancers2025

HER2 Interactome Profiling Reveals MARCKS as a Candidate Marker Associated with Aggressive Breast Cancer.

Atsushi Yokoyama, Shun Sawatsubashi, Akiko Ebata, Yasuhiro Miki, Yuri Otsubo, Takashi Suzuki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Atsushi YokoyamaDepartment of Molecular Endocrinology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.ORCID 0000-0003-2842-4334
Shun SawatsubashiResearch and Innovation Liaison Office, Institute of Advanced Medical Sciences, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan.ORCID 0000-0003-3093-8334
Akiko EbataDepartment of Breast and Endocrine Surgical Oncology Graduate School of Medicine Tohoku University, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan.ORCID 0000-0003-2420-6401
Yasuhiro MikiDepartment of Anatomic Pathology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.ORCID 0000-0003-3618-5652
Yuri OtsuboDepartment of Molecular Endocrinology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
Takashi SuzukiDepartment of Anatomic Pathology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.ORCID 0000-0003-0195-815X

Funding

Institute of Advanced Medical Sciences, Tokushima University Joint Usage and Joint Research ProgramsJapan Society for the Promotion of Science 21K11439Japan Society for the Promotion of Science 24K10533Suzuken (Japan) Suzuken Memorial Foundation
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biomarkerbreast cancerHER2interactomeMARCKSMass SpectrometryproteomicsRIMETCGA

Identifiers

PMID40940979
PMCPMC12428157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.